- Published on
Diagnostic Tests – PET Scanning
1. What Is a PET Scan?
A PET scan, or positron emission tomography, is an imaging technique that evaluates the metabolic activity of tissues rather than just their anatomical structure. Unlike CT or MRI, which show size, shape, and location, a PET scan uses a radioactive glucose analog—most commonly 18-fluorodeoxyglucose (FDG)—to assess how active a lesion is metabolically. Cancer cells typically have high glucose consumption, so they absorb more FDG and appear as areas of increased signal. PET scanning is noninvasive and is frequently used to determine whether a mass seen on other imaging studies is biologically active or whether it represents benign or inactive tissue.
2. What Makes a PET Scan Abnormal?
A PET scan is considered abnormal when there is increased uptake of FDG, indicating heightened metabolic activity. Malignant cells consume glucose rapidly because of their elevated growth and division rates, so they typically “light up” on PET imaging. Some infections, granulomatous diseases (e.g., TB, sarcoidosis), and inflammatory processes can also show increased uptake, which is why PET is not 100% specific for cancer. However, a low or absent uptake suggests that a lesion is metabolically inactive or benign, even if it appears concerning on CT or MRI.
3. When Is PET Scan the Correct Answer?
PET scanning is particularly useful when evaluating whether a lesion—such as a lung mass—is truly malignant or whether areas seen on CT represent metastatic disease. In oncology cases, PET is the answer when determining the functional status of a suspicious mass or when assessing for occult metastasis before deciding on surgical management. For example, if a patient is diagnosed with a localized lung tumor, a PET scan helps determine if there are metabolically active lesions elsewhere in the chest or body. If a contralateral mass or mediastinal lymph node lights up on PET, the disease is considered metastatic and surgery is no longer curative. Conversely, if additional lesions show low uptake, they are likely benign, and the patient may proceed safely to surgery to remove the primary tumor.
1. What Is a PET Scan?
A PET scan, or positron emission tomography, is an imaging technique that evaluates the metabolic activity of tissues rather than just their anatomical structure. Unlike CT or MRI, which show size, shape, and location, a PET scan uses a radioactive glucose analog—most commonly 18-fluorodeoxyglucose (FDG)—to assess how active a lesion is metabolically. Cancer cells typically have high glucose consumption, so they absorb more FDG and appear as areas of increased signal. PET scanning is noninvasive and is frequently used to determine whether a mass seen on other imaging studies is biologically active or whether it represents benign or inactive tissue.
2. What Makes a PET Scan Abnormal?
A PET scan is considered abnormal when there is increased uptake of FDG, indicating heightened metabolic activity. Malignant cells consume glucose rapidly because of their elevated growth and division rates, so they typically “light up” on PET imaging. Some infections, granulomatous diseases (e.g., TB, sarcoidosis), and inflammatory processes can also show increased uptake, which is why PET is not 100% specific for cancer. However, a low or absent uptake suggests that a lesion is metabolically inactive or benign, even if it appears concerning on CT or MRI.
3. When Is PET Scan the Correct Answer?
PET scanning is particularly useful when evaluating whether a lesion—such as a lung mass—is truly malignant or whether areas seen on CT represent metastatic disease. In oncology cases, PET is the answer when determining the functional status of a suspicious mass or when assessing for occult metastasis before deciding on surgical management. For example, if a patient is diagnosed with a localized lung tumor, a PET scan helps determine if there are metabolically active lesions elsewhere in the chest or body. If a contralateral mass or mediastinal lymph node lights up on PET, the disease is considered metastatic and surgery is no longer curative. Conversely, if additional lesions show low uptake, they are likely benign, and the patient may proceed safely to surgery to remove the primary tumor.
0 Comments
